XKRX
078160
Market cap90mUSD
Jul 10, Last price
9,240.00KRW
1D
8.96%
1Q
-54.37%
Jan 2017
-82.98%
IPO
-86.11%
Name
Medipost Co Ltd
Chart & Performance
P/E
—
P/S
2.03
EPS
—
Div Yield, %
—
Shrs. gr., 5y
17.33%
Rev. gr., 5y
8.66%
Revenues
73.66b
+4.25%
Net income
-85.40b
L+36.58%
CFO
-57.15b
L+53.34%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Medipost Co., Ltd. is a biotechnology firm dedicated to the creation and manufacturing of stem cell-based products. Its diverse operations are categorized into several divisions: the Cord Blood Bank, which specializes in the collection and storage of newborn umbilical cord stem cells; Stem Cell Therapy, focused on producing allogeneic stem cell pharmaceuticals; Health Functional Food, offering various vitamins and nutritional supplements; and the Import and Distribution of Natural Cosmetics division, responsible for the sales and marketing of natural cosmetic products sourced from Pevonia Inc. Additionally, the company provides comprehensive Healthcare Services, encompassing bizcare, insu-care, affiliate programs, telehealth, and medical devices, accessible via web, mobile, and call centers. Established on June 26, 2000, by Yoon-Sun Yang and Won-Il Oh, Medipost Co., Ltd. is headquartered in Seongnam, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||